Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres

Hyeong Cheol Oh, Jin Kyoung Shim, Junseong Park, Ji Hyun Lee, Ran Joo Choi, Nam Hee Kim, Hyun Sil Kim, Ju Hyung Moon, Eui Hyun Kim, Jong Hee Chang, Jong In Yook, Seok Gu Kang

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Purpose: Glioblastoma (GBM) is the most aggressive type of brain tumor and has poor survival outcomes, even after a combination of surgery, radiotherapy, and chemotherapy. Temozolomide is the only agent that has been shown to be effective against GBM, suggesting that combination of temozolomide with other agents may be more effective. Niclosamide, an FDA approved anthelmintic agent, has shown anti-cancer effects against human colon, breast, prostate cancers as well as GBM. However, the efficacy of the combination of niclosamide with temozolomide against GBM tumorspheres (TSs) has not been determined. We hypothesized that the combined treatment could effectively suppress GBM TSs. Methods: GBM TSs (TS15-88, GSC11) were treated with niclosamide and/or temozolomide. Combined effects of two drugs were evaluated by measuring viability, neurosphere formation, and 3D-invasion in collagen matrix. Transcriptional profiles of GBM TS were analyzed using RNA sequencing. In vivo anticancer efficacy of combined drugs was tested in a mouse orthotopic xenograft model. Results: Combination treatment of niclosamide and temozolomide significantly inhibited the cell viability, stemness, and invasive properties of GBM TSs. This combined treatment significantly down-regulated the expression of epithelial mesenchymal transition-related markers, Zeb1, N-cadherin, and β-catenin. The combined treatment also significantly decreased tumor growth in orthotopic xenograft models. Conclusion: The combination of niclosamide and temozolomide effectively decreased the stemness and invasive properties of GBM TSs, suggesting that this regimen may be therapeutically effective in treating patients with GBM.

Original languageEnglish
Pages (from-to)2817-2828
Number of pages12
JournalJournal of cancer research and clinical oncology
Volume146
Issue number11
DOIs
Publication statusPublished - 2020 Nov 1

Bibliographical note

Funding Information:
The GBM TS cell line GSC11, derived from primary GBM specimens was provided by Dr. Frederick F. Lang, M. D. Anderson Cancer Center, Houston, Texas, USA. This work was supported by grants from the Korean Health Technology R&D Project, the Ministry of Health & Welfare, Republic of Korea (HI17C2586 and HI14C1324), and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (NRF-2019R1A2C3004155), and the Bio & Medical Technology Development Program of the National Research Foundation (NRF) & funded by the Korean government (MSIP&MOHW) (NRF-2016M3A9B6945832)

Funding Information:
The GBM TS cell line GSC11, derived from primary GBM specimens was provided by Dr. Frederick F. Lang, M. D. Anderson Cancer Center, Houston, Texas, USA. This work was supported by grants from the Korean Health Technology R&D Project, the Ministry of Health & Welfare, Republic of Korea (HI17C2586 and HI14C1324), and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (NRF-2019R1A2C3004155), and the Bio & Medical Technology Development Program of the National Research Foundation (NRF) & funded by the Korean government (MSIP&MOHW) (NRF-2016M3A9B6945832)

Publisher Copyright:
© 2020, The Author(s).

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres'. Together they form a unique fingerprint.

Cite this